Cargando…
Clinical, molecular, and immune correlates of the Immunotherapy Response Score in patients with advanced urothelial carcinoma under atezolizumab monotherapy: analysis of the phase II IMvigor210 trial
BACKGROUND: In the advanced urothelial carcinoma (aUC) scenario there are no consistent immune checkpoint blockade predictive biomarkers. Recently a novel pan-tumor molecular tissue-based biomarker, the Immunotherapy Response Score (IRS), has been proposed. We conducted a retrospective study to vali...
Autores principales: | Ferreiro-Pantín, M., Anido-Herranz, U., Betancor, Y.Z., Cebey-López, V., León-Mateos, L., García-González, J., García-Acuña, S.M., Fernández-Díaz, N., Tubio, J.M.C., López-López, R., Ruiz-Bañobre, J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485401/ https://www.ncbi.nlm.nih.gov/pubmed/37516059 http://dx.doi.org/10.1016/j.esmoop.2023.101611 |
Ejemplares similares
-
Atezolizumab in locally advanced or metastatic urothelial cancer: a pooled analysis from the Spanish patients of the IMvigor 210 cohort 2 and 211 studies
por: Sotelo, M., et al.
Publicado: (2020) -
Role of atezolizumab therapy combined with platinum-based chemotherapy in untreated metastatic urothelial carcinoma – The new landscapes (IMvigor130 trial)
por: Misra, Ankit
Publicado: (2021) -
Rethinking prognostic factors in locally advanced or metastatic urothelial carcinoma in the immune checkpoint blockade era: a multicenter retrospective study
por: Ruiz-Bañobre, J., et al.
Publicado: (2021) -
Long-term Response to Nivolumab and Acute Renal Failure in a Patient with Metastatic Papillary Renal Cell Carcinoma and a PD-L1 Tumor Expression Increased with Sunitinib Therapy: A Case Report
por: Ruiz-Bañobre, Juan, et al.
Publicado: (2016) -
MSIMEP: Predicting microsatellite instability from microarray DNA methylation tumor profiles
por: Santamarina-García, Martín, et al.
Publicado: (2023)